Related Experiment Videos
Immunotherapy in conjunction with autologous bone marrow transplantation
A Eckerstein1, S Slavin, L Weiss
1Department of Bone Marrow Transplantation, Hadassah University Hospital, Jerusalem, Israel.
Bone Marrow Transplantation
|January 1, 1990
Summary
High-dose chemoradiotherapy for bone marrow transplantation (BMT) can eradicate leukemia but residual cancer cells may persist. This study explores immunotherapy and IL2 to eliminate these remaining BCL1 lymphoma cells in mice.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- High-dose chemoradiotherapy followed by autologous bone marrow transplantation (BMT) is a standard treatment for hematological malignancies.
- Relapses after BMT suggest that residual tumor cells survive treatment, necessitating further therapeutic strategies.
Purpose of the Study:
- To investigate methods for controlling residual leukemia/lymphoma cells that escape chemoradiotherapy.
- To evaluate cellular adoptive immunotherapy and amplification of natural defense mechanisms as post-BMT consolidation strategies.
Main Methods:
- Utilizing a murine model of BCL1 leukemia/lymphoma disease.
- Employing recombinant human Interleukin-2 (IL2) to amplify natural defense mechanisms.
- Investigating cellular adoptive immunotherapy approaches.
Main Results:
- Preliminary investigation into novel therapeutic strategies for residual disease.
- Focus on enhancing the host's immune response against remaining cancer cells.
Conclusions:
- Residual tumor cells pose a significant challenge after conventional BMT.
- Cellular immunotherapy and IL2-mediated immune amplification show promise for eradicating persistent leukemia/lymphoma cells.